Rodriguez-Del Rio Estela, Frande-Cabanes Elisabet, Tobes Raquel, Pareja Eduardo, Lecea-Cuello M Jesús, Ruiz-Sáez Marta, Carrasco-Marín Eugenio, Alvarez-Dominguez Carmen
Grupo de Genómica, Proteómica de Infecciones Bacterianas e Inflamación Fundación Marqués de Valdecilla-IFIMAV and Hospital Santa Cruz de Liencres (HUMV). Santander. Cantabria Spain.
Int J Biochem Mol Biol. 2011;2(3):207-18. Epub 2011 Jul 15.
LLO is the major immuno-dominant antigen in listeriosis and is also required for protective immunity. Two forms of LLO can be observed in endosomal membranes, a LLO intact form and a Ctsd-processed LLO(1-491) form. Endosomes obtained from resting macrophages contained only LLO intact forms, while endosomes obtained from IFN-activated macrophages contained both forms. Both types of endosomes elicited LLO(90-91)/CD8(+) and LLO(189-201)/CD4(+) specific immune responses. However, only endosomes containing the Ctsd-processed LLO(1-491) form showed significant CD4(+) and CD8(+) T cell responses similar to LM infected bone marrow derived macrophages and characteristic of protective Listeria immunity. Moreover, endosomes with intact LLO could not confer protection as vaccine carriers against murine listeriosis. While endosomes with Ctsd-processed LLO(1-491) form showed a moderate ability, slightly lower than high efficiency vaccine vectors as MØ infected with LM. These studies argue that all cell-free membrane vesicles might serve as valid vaccine carriers against infectious agents. Exclusively those cell-free vesicles MIIC competent for LLO processing are protective vaccines vectors since they recruit significant numbers of mature dendritic cells to the vaccination sites and contain a LLO(1-491) form that might be accessible for MHC class I and class II antigen presentation.
LLO是李斯特菌病中的主要免疫显性抗原,也是保护性免疫所必需的。在内体膜中可观察到两种形式的LLO,一种是LLO完整形式,另一种是经组织蛋白酶D处理的LLO(1 - 491)形式。从静息巨噬细胞获得的内体仅含有LLO完整形式,而从干扰素激活的巨噬细胞获得的内体则含有两种形式。这两种类型的内体均引发了LLO(90 - 91)/CD8(+)和LLO(189 - 201)/CD4(+)特异性免疫反应。然而,只有含有经组织蛋白酶D处理的LLO(1 - 491)形式的内体显示出与感染李斯特菌的骨髓来源巨噬细胞相似的显著CD4(+)和CD8(+) T细胞反应,这是李斯特菌保护性免疫的特征。此外,具有完整LLO的内体不能作为针对鼠李斯特菌病的疫苗载体提供保护。而具有经组织蛋白酶D处理的LLO(1 - 491)形式的内体显示出中等能力,略低于感染李斯特菌的巨噬细胞作为高效疫苗载体的能力。这些研究表明,所有无细胞膜囊泡都可能作为针对感染因子的有效疫苗载体。只有那些能够处理LLO的无细胞囊泡MIIC才是保护性疫苗载体,因为它们能将大量成熟树突状细胞募集到接种部位,并且含有一种可能可供MHC I类和II类抗原呈递的LLO(1 - 491)形式。